EuroPCR 2013 in Paris, France
Please check back for updates.
CardioKinetix Announces Successful Parachute
Paris and Menlo Park, Calif – CardioKinetix Inc, a medical device company pioneering a catheter-based treatment for heart
CardioKinetix Announces Positive Clinical
Meta-Analysis Presented at EuroPCR Substantiate Potential of Breakthrough Treatment for Heart Failure Patients; Largest
CardioKinetix Initiates Landmark Study
Randomized Multicenter PARACHUTE IV Clinical Trial Will Compare Minimally Invasive Device to Optimal Medical
“We continue to be encouraged by the early clinical results demonstrated by the Parachute® implant. In all of our previous studies we have seen similar improvements in treated heart failure patients.”Thomas Engels, Vice President of Clinical Affairs of CardioKinetix Inc.